| Page 67 | Aplastic Anemia and MDS International Foundation (AAMDSIF)

Cancer and Coronavirus Disease 2019 (COVID-19)—Facing the “C Words”

By Urvi A. Shah, MD from JAMA Oncology

Dr. Eunice Wang discusses Secondary MDS

Dr. Eunice Wang explains the origin and treatment of secondary MDS. Dr. Wang is the Chief of the Leukemia Service at Roswell Park Comprehensive Center.

Dr. David Steensma discusses MDS and toxins with Leigh Clark, Patient Educator

Dr. David Steensma discusses MDS and toxins with Leigh Clark, Patient Educator. Dr. Steensma is an associate professor at Harvard Medical School and faculty member in the leukemia program at the Dana-Farber Cancer Institute and Brigham and Women's Hospital in Boston, Massachusetts and the Edward P. Evans Chair in MDS at Dana-Farber Cancer Institute

COVID-19 outcomes in patients with hematologic disease

To the Editor:

Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide

Key Points

Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide

Author(s):

DeZern AE, Zahurak ML, Symons HJ, Cooke KR, Rosner GL, Gladstone DE, Huff CA, Swinnen LJ, Imus P, Borrello I, Wagner-Johnston N, Ambinder RF, Luznik L, Bolaños-Meade J, Fuchs EJ, Jones RJ, Brodsky RA

Primary Author:

DeZern AE

Journal Title:

Blood Advances

Original Publication Date:

Apr 2020

Severe

Bone Marrow Disease(s):

Aplastic Anemia

Haploidentical hematopoietic stem cell transplantation in aplastic anemia: a systematic review and meta-analysis of clinical outcome on behalf of the severe aplastic anemia working party of the European group for blood and marrow transplantation (SAAWP of

Author(s):

ElGohary G, El Fakih R, de Latour R, Risitano A, Marsh J, Schrezenmeier H, Gluckman E, Höchsmann B, Pierri F, Halkes C, Alzahrani H, De la Fuente J, Cesaro S, Alahmari A, Ahmed SO, Passweg J, Dufour C, Bacigalupo A, Aljurf M

Primary Author:

ElGohary G

Journal Title:

Bone Marrow Transplantation

Original Publication Date:

Apr 2020

Bone Marrow Disease(s):

Aplastic Anemia

Rewriting the rules for care of MDS and AML patients in the time of COVID-19

Author(s):

Raza A, Assal A, Ali AM, Jurcic JG

Primary Author:

Raza A

Journal Title:

Leukemia Research Reports

Original Publication Date:

Apr 2020

The care of patients with

Bone Marrow Disease(s):

Alcohol use is not a significant contributor to myelodysplastic syndromes

Author(s):

Duffy EA, Nguyen PL, Cioc A, Warlick E, Roesler MA, Poynter JN

Primary Author:

Duffy EA

Journal Title:

Cancer Causes & Control : CCC

Original Publication Date:

Apr 2020

Abstract

PURPOSE:

Bone Marrow Disease(s):

Myelodysplastic Syndromes (MDS)

Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities

Author(s):

Sallman DA, Barnard J, Al Ali NH, Garcia-Manero G, Sekeres MA, DeZern A, Steensma DP, Roboz G, Jabbour E, Maciejewski JP, Pierce S, Padron E, Lancet JE, Kantarjian H, List AF, Komrokji RS

Primary Author:

Sallman DA

Journal Title:

Clinical Lymphoma , Myeloma & Leukemia

Original Publication Date:

Mar 2020

BACKGROUND:

Bone Marrow Disease(s):

Myelodysplastic Syndromes (MDS)